Lupin will get USFDA nod to promote hypertension treatment tablets

As per IMS MAT June 2017 data, Nadolol tablets USP in the three strengths had annual sales of around USD 109.8 million in the US, Lupin said.According to IMS Pad June 2017 data, Nadolol tablets USP within the three strengths had annual sales close to USD 109.8 million in america, Lupin stated.

NEW DELHI: Drug firm Lupin today stated it’s received final approval in the US health regulator to promote generic Nadolol tablets, used to treat hypertension, within the American market.

The organization has gotten final approval to promote its Nadolol tablets USP, 20 mg, 40 mg and 80 mg in the U . s . States Fda (USFDA), Lupin stated inside a filing to BSE.

The merchandise is really a generic form of US WorldMeds LLC’s Corgard tablets within the same strengths, it added.

According to IMS Pad June 2017 data, Nadolol tablets USP within the three strengths had annual sales close to USD 109.8 million in america, Lupin stated.

The tablets are indicated for control over patients with angina pectoris and to treat hypertension, it added.

Shares of Lupin today closed at Rs 1,038.15 on BSE, lower .40 percent from previous close.

Leave a Reply

Your email address will not be published. Required fields are marked *